0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Antibody > Nucleocapsid protein > NUN-S41

Anti-SARS-CoV-2 Nucleocapsid Antibody, Human IgG1 (AS41)

Order Now

  • Source
    Anti-SARS-CoV-2 Nucleocapsid Antibody, Human IgG1 (AS41) (NUN-S41) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). As verified by binding test with N-NTD (Cat. No. NUN-C5143) and N-CTD (Cat. No. NUN-C5145) protein, this antibody can only bind to N-CTD (AA Ser 255 - Pro 364). ELISA test validated that this antibody can bind multiple N protein variants (Cat. No. NUN-C52H8, NUN-C52Hc, NUN-C52Hd) with similar affinity as compared to the wild type N protein (Cat. No. NUN-C5227).
  • Clone

    AS41

  • Isotype

    Human IgG1 | Kappa

  • Antibody Type

    Recombinant Monoclonal

  • Reactivity

    Virus

  • Specificity

    This product can recognize SARS-CoV-2 and SARS-CoV Nucleocapsid protein. No cross-reactivity is detected with nucleocapsid protein of other coronaviruses, including MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1.

  • Application
    ApplicationRecommended Usage
    ELISA0.1-10 ng/mL
  • Purity

    >95% as determined by SDS-PAGE.

  • Purification

    Protein A purified/ Protein G purified

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Nucleocapsid protein SDS-PAGE

Anti-SARS-CoV-2 Nucleocapsid Antibody, Human IgG1 (AS41) on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
 Nucleocapsid protein ELISA

Immobilized SARS-CoV-2 Nucleocapsid protein, His Tag (Cat. No. NUN-C5227) at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Nucleocapsid Antibody, Human IgG1 (AS41) (Cat. No. NUN-S41) with a linear range of 0.08-1 ng/mL (QC tested).

 Nucleocapsid protein ELISA

Immobilized Anti-SARS-CoV-2 Nucleocapsid Antibody, Human IgG1 (AS41) (Cat. No. NUN-S41) at 1 μg/mL (100 μL/well) can bind SARS-CoV-2 Nucleocapsid protein, His Tag (B.1.1.529/Omicron) (Cat. No. NUN-C52Ht) with a linear range of 0.1-3 ng/mL (Routinely tested).

  • Background
    Nucleocapsid (N) protein is the most abundant protein found in coronavirus. CoV N protein is a highly immunogenic phosphoprotein important for viral genome replication and modulation of cell signaling pathways. It was first identified by a research team while they were screening for ADP-ribosylated proteins during coronavirus (CoV) infection (Grunewald M. E., et al. 2017, Virology; 517: 62-68). The array of diverse functional activities accommodated in N protein makes it more than a structural protein but also an interesting target in the development of antiviral therapeutics. Because of the conservation of N protein sequence and its strong immunogenicity, N protein of coronavirus is chosen as a diagnostic tool.
  • Clinical and Translational Updates

Comments (0)


ETA des produits en stock: 2 jours ouvrables

Price(EUR) : €380.00

Price(EUR) : €2780.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:1 Details
  • Latest Research Phase:Phase 1 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Laisser un message